A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
Alkermes gets decisive thumbs down
ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
Amicus’s Pompe disease setback doesn’t dent gene therapy enthusiasm
The FDA asks Amicus for more data on its Pompe disease candidate, but the company is already looking towards a Fabry disease gene therapy, and has made a remarkable…
